Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- CCCC
- Price
- 2.18
- Stock movement up
- +0.06 (2.83%)
- Company name
- C4 Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 211.27M
- Ent value
- 263.54M
- Price/Sales
- 7.02
- Price/Book
- 1.37
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -8.02%
- 1 year return (CAGR)
- -43.38%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CCCC does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 7.02 |
| Price to Book | 1.37 |
| EV to Sales | 8.75 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 96.91M |
| EPS (TTM) | -1.64 |
| FCF per share (TTM) | -1.31 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 30.11M |
| Gross profit (TTM) | 28.34M |
| Operating income (TTM) | -129.79M |
| Net income (TTM) | -119.08M |
| EPS (TTM) | -1.64 |
| EPS (1y forward) | -1.29 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 94.13% |
| Operating margin (TTM) | -431.07% |
| Profit margin (TTM) | -395.51% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 58.81M |
| Net receivables | 6.54M |
| Total current assets | 206.86M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 57.49M |
| Total assets | 265.49M |
| Accounts payable | 1.33M |
| Short/Current long term debt | 61.46M |
| Total current liabilities | 35.95M |
| Total liabilities | 111.08M |
| Shareholder's equity | 154.41M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -94.48M |
| Capital expenditures (TTM) | 600.00K |
| Free cash flow (TTM) | -95.08M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -77.12% |
| Return on Assets | -44.85% |
| Return on Invested Capital | -74.14% |
| Cash Return on Invested Capital | -59.19% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.14 |
| Daily high | 2.23 |
| Daily low | 2.13 |
| Daily Volume | 779K |
| All-time high | 50.50 |
| 1y analyst estimate | 11.14 |
| Beta | 2.89 |
| EPS (TTM) | -1.64 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| CCCC | S&P500 | |
| Current price drop from All-time high | -95.68% | -0.89% |
| Highest price drop | -97.82% | -19.00% |
| Date of highest drop | 16 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -94.52% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
211.27M
Marketcap category
Small-cap
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Employees
110
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page